Detalles de la búsqueda
1.
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
J Allergy Clin Immunol
; 149(6): 2010-2020.e8, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34767869
2.
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Br J Clin Pharmacol
; 86(9): 1849-1859, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32198939
3.
Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS.
Anal Chem
; 91(13): 8443-8452, 2019 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31247719
4.
Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).
Crit Care Med
; 47(5): 632-642, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30747773
5.
Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants.
Eur J Clin Pharmacol
; 73(6): 689-698, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28265691
6.
First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2.
Clin Transl Sci
; 16(1): 151-164, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36325947
7.
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.
Lancet Rheumatol
; 5(5): e263-e273, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38251590
8.
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab.
Intensive Care Med
; 45(10): 1360-1371, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31576433
9.
Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.
Sci Transl Med
; 11(502)2019 07 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31341059
10.
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
J Med Chem
; 62(7): 3228-3250, 2019 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30893553
11.
Suppressor of cytokine signaling 1 is required for the differentiation of CD4+ T cells.
Nat Immunol
; 6(7): 715-21, 2005 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15924143
Resultados
1 -
11
de 11
1
Próxima >
>>